Device approvals drop, but the FDA has a plan
Increased headcount should allow the FDA to up the number of approvals – but not quite yet.
Venture financing holds steady for device makers
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
The other shoe finally drops for device dealmaking
A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.
Despair engulfs smaller device companies
The nightmare on the public markets is not confined to the bigger groups.
Big medtech's share price bloodbath
The worst half-year period for a decade leaves the biggest medical device companies half a trillion dollars poorer.
Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Are we there yet?
Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.
The retrenchment begins for venture funding
The gloomy climate for biotech is now taking its toll on private companies too.
